
Ductal carcinoma in situ is an extremely early form of breast cancer. When it occurs, the cancer cells are contained within a breast milk duct, and the breast tissue is still free of cancerous cells. A common term for this type of breast cancer is DCIS. This type of breast cancer is sometimes referred to as stage 0, noninvasive, or preinvasive.
DCIS is usually found on a mammogram that is done to screen for breast cancer or to investigate a bulge in the breast. There is a minimal chance that DCIS will become invasive and threaten life. However, it must be evaluated, and treatment options must be considered.
DCIS is often treated with surgery. Other treatments may include hormone therapy or radiation therapy in addition to surgery.
Ductal Cell Carcinoma in Situ (DCIS) must be treated early to lower the chance of recurrence and spread to other body areas, as well as to stop it from developing into invasive breast cancer. Early detection reduces the psychological and physical effects of more invasive surgeries, increases survival rates, and permits breast-conserving therapy. Patients who receive immediate treatment for DCIS have a better prognosis and a higher quality of life, and their chances of the disease developing into something invasive or life-threatening are significantly decreased.
Usually, there are no symptoms associated with ductal carcinoma in situ. DCIS is another name for this early stage of breast cancer.
DCIS can occasionally result in symptoms like:
Mammography is typically where DCIS is detected. In breast tissue, it manifests as microscopic calcium particles. These are calcifications, which are deposits of calcium.
Causes
A non-malignant breast cancer that starts in the milk ducts is referred to as ductal carcinoma in situ (DCIS). While their exact cause is not known, risk factors are age (typically greater than 50), radiation, family history or genetic defects (e.g., BRCA1/2), hormonal imbalances, and personal history of benign breast disease.
The risk can also be increased by lifestyle factors such as obesity, alcohol consumption, and lack of exercise, as well as previous reproductive history. Early detection screening is key to the management of DCIS.
Risk Factors
Ductal Carcinoma In Situ (DCIS) is a non-invasive form of breast cancer that is localised within the milk ducts. The latest developments involve targeted treatments and hormone therapies to treat specific tumour features. Major medical centres provide expert care for DCIS using advanced technologies and multidisciplinary treatment to maximise patient outcomes. Treatment usually consists of surgical methods like lumpectomy or mastectomy, followed by radiation therapy to minimise the risk of recurrence.
Lumpectomy: The breast cancer and a portion of the surrounding normal tissue are cut out during a lumpectomy. There is no removal of the rest of the breast tissue. Wide local excision and breast-conserving surgery are alternative names for this procedure. Most patients who have a lumpectomy also undergo radiation therapy.
Mastectomy: The removal of all the breast tissue by operation is called a mastectomy. If you prefer, breast reconstruction to re-form the appearance of the breast may be performed at the same time or later on.
Cost Start From USD 3000 - USD 4000Explore Options
Hormone therapy: Endocrine therapy, also referred to as hormone therapy, involves using drugs that prevent the body from making specific hormones. It is applied in the treatment of breast cancers that are estrogen and progesterone-sensitive.
Cost Start From USD 3500 - USD 5500Explore Options
Radiation Therapy: To reduce the risk of recurrence, radiation therapy is often given after surgery for ductal carcinoma in situ (DCIS). It is typically recommended following a lumpectomy, especially if the tumour is large or has high-risk features. High-energy X-rays are employed in the treatment to locate and kill any remaining cancer cells in the breast tissue. Radiation therapy significantly decreases the possibility that DCIS could recur.
Mammography is the most common screening method for detecting breast calcifications that may indicate DCIS.
Breast ultrasound is often used together with mammography to evaluate areas of concern further.
MRI: Provides high-resolution images and helps to determine the extent of DCIS.
Biopsy: The best test for diagnosing DCIS is a biopsy, in which tissue is removed from the suspicious region to determine whether cancer cells are present.
MediRehab (chain of Rehab centres - Part of MediGence) provides comprehensive rehabilitation services designed to support Duct carcinoma in situ patients in India. These services include:









Hyderabad, India
American Oncology Institute located in Hyderabad, India is accredited by AAAHC. Also listed below are some of the most prominent infrastructural details:

Chennai, India
MIOT started its journey with only 70 beds and focusing on Orthopedics and Trauma care. However, we grew into a multi-specialty hospital with time. MIOT is now a 1000-bedded hospital and can offer an extensive range of services across 63 specialties. The state of art laboratory of our hospital is ranked 8th internationally. We have 21 super-specialty operation theaters equipped with cutting-edge technology to help our doctors with complex procedures.
We take great care to make our patient rooms comfortable enough. The patient rooms get plenty of fresh air as well as natural light. The soothing views from the rooms do not let the patients feel cut off from the outside world. We use separate entrances for emergency patients, out-patients, in-patients, and their attendants. We put our patients’ safety first which is why we use a superior air system to ensure a near-zero infection healthy environment.
Apart from that, MIOT’s 24 hours blood bank provides all kinds of blood work related services which include blood collection to component separation. This state-of-art blood bank alone handles more than 30,000 units of blood over the course of a year. Every month around 600 blood transfusions are managed by this blood bank.
MIOT’s SIGNA Pioneer 3T MRI machine is made with noise reduction technology. This silent MRI machine can deliver superior quality neuroimages without wasting any time. The department of Radiology and Imaging Sciences can give tough competition to any international hospital with its advanced technology and accuracy.
The PET CT service at MIOT International is the first of its kind in South India enabling better and more accurate diagnosis than earlier. The superior diagnosis is also possible for the two digital cath labs at MIOT Heart Revive center.
We also have a physiotherapy team where a team of highly efficient physiotherapists deals with the mobility and functional disability issues of our patients. They listen to the patients carefully to identify the root of the pain and use therapeutic exercises to reduce their pain.
The CCU of MIOT is something to be proud of. The specially-trained staff of this unit is dedicated to ensuring top-quality medical support to serious patients. This unit along with the MIOT International Laboratory is the backbone of our facility.
Furthermore, what makes MIOT unique is our Telemedicine service. In the new normal, we are trying everything to reach our patients. Our one of its kind Telemedicine service connects our patients to our 250 full-time doctors over email, phone, chat and video consultations.

Gurugram, India
Sanar International Hospital is a multispeciality hospital based on Golf Course Road in Gurugram, a part of Delhi NCR. It was founded in 2018 and houses one of the most comprehensive and advanced surgical care specialties. This 150-bedded facility is committed to providing the best patient experiences and healthcare services is the core of the hospital’s mission. Staffed by a group of visionary and competent medical professionals who are well-versed in their fields and eminent for their empathy and understanding, Sanar International Hospital provides optimal care to its patients, making it a popular
Specialties in the Hospital such as Heart, Bone, and Joint neurosciences, Cancer, Kidney and Liver Transplant, and other successful procedures along with experienced medical professionals have made a mark for themselves among domestic patients and international patients who come to India to have the finest healthcare services. It follows strict international practices and believes that the centricity of the patient is essential for providing high-quality care through world-class infrastructure and state-of-the-art facilities. The technologies offered by the Hospital include Digital X-rays, MRI, CT, Ultrasound, transfusion medicine, pharmacy, laboratory services, 24 hrs emergency and ambulance services.
It offers more than 20 plus specialties such as General Medicine, Anesthesiology, Cardiac Sciences, Ophthalmology, Gastroenterology, Hematology, Orthopedics, General Surgery & Surgical, Cardiothoracic Surgery, Hepato Biliary Surgery, Pediatrics, Liver Transplantation, and Critical Care Medicine. The Hospital has a highly skilled medical staff of neuro-anesthetists, neurologists, specialized neurocritical care experts, neurosurgeons neuropsychologists, and neuropsychiatrists. There are specific centers for the treatment of epilepsy, stroke, brain tumors, movement disorders, spinal problems, and headaches.
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
India is one of the most popular destinations for treating ductal carcinoma in situ (DCIS) due to its world-class medical centres, expert physicians, and state-of-the-art facilities. Treatment costs are significantly lower here than in many Western countries, but the quality is excellent and affordable. In addition, India provides total medical care, such as radiation, surgery, and rehabilitation, and it actively welcomes foreign patients through medical tourism.
Yes, mammography can often detect ductal carcinoma in situ (DCIS). DCIS usually appears as microcalcifications, microscopic calcium deposits that appear as white specks on X-rays. Microcalcifications can also occur with benign conditions, but when they occur in specific patterns, they can be a marker for DCIS. Mammograms are a key early detection method for DCIS, often before symptoms develop.
In India, a biopsy is the gold standard for diagnosing ductal carcinoma in situ (DCIS). While mammograms and other imaging tests can identify problematic spots, a biopsy is necessary to collect a tissue sample for microscopic analysis. Doctors can use this to effectively diagnose DCIS, evaluate its features, and choose the best course of treatment.
In India, ductal carcinoma in situ (DCIS) often needs surgery, although this depends on the individual case. Based on the size, location, and other features of the DCIS, the most frequent surgical options are mastectomy (breast removal) or lumpectomy (tumour removal).
Surgery is not always needed for DCIS, especially if the issue is detected early and can be treated with hormone therapy or radiation. After consultation with the medical team, the choice is made according to the patient's condition and personal preferences.
Mastectomy can be suggested for Ductal Carcinoma In Situ (DCIS) in India if the DCIS is large or widespread or if it occurs in several locations within the breast so that breast-conserving surgery such as lumpectomy is not as effective. It can also be suggested if the patient is at high risk of recurrence or if prior surgery has not worked to remove the cancer.
Radiation therapy is often recommended in Indian healthcare environments for ductal carcinoma in situ (DCIS), particularly after a lumpectomy. It targets any remaining breast cancer cells, reducing the risk of recurrence. However, radiation therapy is not required for all DCIS patients. Tumor size, margins, grade, and other risk factors affect the decision.
In Indian patients, ductal carcinoma in situ (DCIS) may recur after treatment; the risk is low if proper treatment is undertaken. The opposite or the same breast (local recurrence) can suffer from recurrence. Several factors, such as the grade of DCIS, the surgical margins, the application of radiation therapy, and the patient's overall condition, can influence the risk of recurrence. Imaging tests, monitoring, and follow-up treatment are essential in detecting early recurrence.
Women with Ductal Carcinoma In Situ (DCIS) in India often have very high survival rates; women who receive appropriate therapy have a five-year survival of nearly 90%. The chances of full recovery are significantly enhanced by early detection through screening and timely therapies such as surgery, radiation, or hormone therapy since DCIS is curable and non-invasive. Nevertheless, several variables, such as the tumour's size, grade, and treatment plan, may influence survival rates.